News

Final Dividend Announcement for Northern 2 VCT PLC Investors

Final Dividend Announcement for Northern 2 VCT PLC Investors

Overview of the Final Dividend Declaration

Northern 2 VCT PLC is excited to announce a proposed final dividend of 1.3 pence per ordinary share. This declaration is expected for the financial year ending 31 March 2025. The payment of this dividend is subject to the approval of shareholders, ensuring a collaborative decision-making process among the invested parties.

Key Dates for Shareholders

Pending shareholder approval, the company plans to distribute the final dividend on 5 September 2025. To ensure that shareholders receive their dividends, it's important to note that only those listed on the register as of 8 August 2025 will qualify for this payment. Shareholders should also be aware that the ex-dividend date is set for 7 August 2025, marking the cutoff for eligibility.

Dividend Investment Scheme Benefits

Northern 2 VCT PLC offers a compelling dividend investment scheme that permits shareholders to reinvest their dividends into new ordinary shares without incurring dealing costs. This initiative not only enhances investment potential but also provides significant tax relief benefits on new VCT share subscriptions. Participating in this scheme can be a smart move for those looking to maximize their investment returns while benefiting from tax-efficient options.

How to Join the Scheme

For detailed information on how to join the dividend investment scheme, shareholders can explore the relevant section on the company's website. This resource provides guidance on the enrollment process, allowing shareholders to take full advantage of the opportunities available to them.

Contact Information for Inquiries

Any questions regarding this dividend announcement or the investment scheme can be directed to Sarah Williams or James Sly at Mercia Fund Management Limited. They can be reached by phone at 0330 223 1430.

Website Information

For more updates, shareholders and potential investors are encouraged to visit the company’s online resources at www.mercia.co.uk/vcts/n2vct/. This website contains essential information pertaining to Northern 2 VCT PLC and the various investment opportunities available.

Conclusion

Northern 2 VCT PLC continues to demonstrate its commitment to rewarding shareholders with dividend distributions while providing smart reinvestment options through its dividend investment scheme. By communicating transparently about the proposed dividend and key dates, the company fosters a sense of trust and engagement with its investors. Stay informed, and make the most of your investment opportunities with Northern 2 VCT PLC (LSE:NTV).

Frequently Asked Questions

What is the proposed final dividend amount for Northern 2 VCT PLC?

The proposed final dividend is 1.3 pence per ordinary share.

When will the final dividend be paid?

The final dividend is set to be paid on 5 September 2025, pending shareholder approval.

What is the ex-dividend date for this payment?

The ex-dividend date is 7 August 2025.

Can shareholders reinvest dividends?

Yes, Northern 2 VCT PLC offers a dividend investment scheme that allows shareholders to reinvest their dividends free of dealing costs.

Who can I contact for more information?

For inquiries, you can contact Sarah Williams or James Sly at Mercia Fund Management Limited, at 0330 223 1430.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 234

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 70

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 115

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 0

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 97

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
SpaceMap Tackles Space Traffic With AI Innovation

Updated Category News Views 0

SpaceMap Takes Aim at the Crowded Space Above You ever look up and wonder what's hurtling above our noggins? More satellites than you can shake a stick at, that's what. And don't even start me on the debris floating around. This ain't just rocket science anymore; it's a crowded dance floor, and someone's gotta manage it. Enter SpaceMap, a plucky South Korean startup that...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 56

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Postpones Asia Cruise Ship Launch Amid Challenges

Updated Category News Views 232

Disney Delays Launch of Its First Asia Cruise Ship Walt Disney Co. (NYSE: DIS) has announced a three-month delay in the inaugural voyage of its first Asia-based cruise ship, the Disney Adventure. Originally set to embark from Singapore on December 15, the new launch date is now March 10, 2026, due to unexpected setbacks in the shipbuilding process. Challenges in...

Continue Reading
Promising Outcomes from ASPIRO Phase 1/2a Trial for Parkinson's

Updated Category News Views 159

Promising Results from Aspen Neuroscience's Clinical Study Aspen Neuroscience has recently shared encouraging insights from the ASPIRO Phase 1/2a clinical trial, focusing on their innovative cell therapy, ANPD001, aimed at treating Parkinson's Disease. This investigational approach leverages autologous dopaminergic neuronal precursor cells (DANPC) that hold the potential...

Continue Reading
Exploring Honeywell Intl's Options Trends and Market Analysis

Updated Category News Views 213

Understanding Honeywell Intl's Current Options Landscape The dynamic environment of finance recently showcased an intriguing shift with notable bearish movements concerning Honeywell Intl. The latest analysis of options trading data for Honeywell Intl (HON) has spotlighted a total of 10 unique trades that have piqued interest among traders. In an examination of the...

Continue Reading
Transforming Business with Google Agentspace and Premier Cloud

Updated Category News Views 217

Transforming Business with Google Agentspace and Premier Cloud Premier Cloud has been recognized as a launch partner for Google Agentspace, Google's innovative new AI platform that aims to revolutionize enterprise search and productivity. This partnership is a significant milestone for Premier Cloud, a prominent Google Cloud Premier Partner, renowned for its expertise in...

Continue Reading
Transforming Biotechnology: A New Era for Advanced Therapies

Updated Category News Views 156

Innovative Biomanufacturing Comes to Saudi Arabia At the forefront of a new biotechnology initiative, a strategic partnership has emerged between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC, unveiling a state-of-the-art Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. This exciting development represents a...

Continue Reading